CTOs on the Move

Mustang Bio

www.mustangbio.com

 
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.mustangbio.com
  • 2 Gansevoort Street 9th Floor
    New York, NY USA 10014
  • Phone: 781.652.4500

Executives

Name Title Contact Details
Knut Niss
Chief Technology Officer Profile

Funding

Mustang Bio raised $20M on 04/01/2019
Mustang Bio raised $75M on 03/08/2022

Similar Companies

CSL

CSL is a global biotech leader that develops and delivers life-saving medicines to treat disorders such as haemophilia and primary immune deficiencies, and vaccines to prevent influenza. They have over 30,000 employees worldwide and are committed to co...

Mylan

Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the-counter (OTC) remedies. We market our products in more than 165 countries and territories, and every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world. Mylans mission is grounded in our belief that every person matters and should have the opportunity to live the healthiest life possible. We have built our business model consistent with this belief, and through it, we are impacting people around the world with each passing year. Providing universal access to medicine is the core purpose of our model. To provide access, we must be able to satisfy the needs of an incredibly diversified global marketplace whose economic and political systems, approaches to delivering and paying for healthcare, languages and traditions, and customer and patient requirements vary by location and over time.

Kindred Pharmacy Services(Pmc Pharmacy Services )

Kindred Pharmacy Services(Pmc Pharmacy Services ) is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Torrent Pharma Inc

Torrent Pharma Inc is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.